Synopsis
Synopsis
0
CEP/COS
0
JDMF
0
KDMF
0
VMF
0
Canada
0
Australia
DRUG PRODUCT COMPOSITIONS
US Medicaid
NA
Annual Reports
NA
Regulatory FDF Prices
NA
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
1. Sacubitril Sodium
2. 149690-05-1
3. Ahu-377 Sodium
4. Sacubitril (sodium)
5. Mop72gep8z
6. Sodium;4-[[(2s,4r)-5-ethoxy-4-methyl-5-oxo-1-(4-phenylphenyl)pentan-2-yl]amino]-4-oxobutanoate
7. Unii-mop72gep8z
8. Sacubitril Sodium Salt
9. Sacubitril Sodium [mi]
10. Schembl21239956
11. Dtxsid90164362
12. Hy-15407b
13. (1,1'-biphenyl)-4-pentanoic Acid, Gamma-((3-carboxy-1-oxopropyl)amino)-alpha-methyl-, 4-ethyl Ester, Sodium Salt (1:1), (alphar,gammas)-
14. Cs-0079358
15. A937423
16. Q27284149
17. (1,1'-biphenyl)-4-pentanoic Acid, .gamma.-((3-carboxy-1-oxopropyl)amino)-.alpha.-methyl-, 4-ethyl Ester, Sodium Salt (1:1), (.alpha.r,.gamma.s)-
18. Sodium 4-(((2s,4r)-1-([1,1'-biphenyl]-4-yl)-5-ethoxy-4-methyl-5-oxopentan-2-yl)amino)-4-oxobutanoate
Molecular Weight | 433.5 g/mol |
---|---|
Molecular Formula | C24H28NNaO5 |
Hydrogen Bond Donor Count | 1 |
Hydrogen Bond Acceptor Count | 5 |
Rotatable Bond Count | 12 |
Exact Mass | 433.18651728 g/mol |
Monoisotopic Mass | 433.18651728 g/mol |
Topological Polar Surface Area | 95.5 Ų |
Heavy Atom Count | 31 |
Formal Charge | 0 |
Complexity | 556 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 2 |
Undefined Atom Stereocenter Count | 0 |
Defined Bond Stereocenter Count | 0 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 2 |
API/FDF Prices: Book a Demo to explore the features and consider upgrading later
API Imports and Exports
Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
---|
Upgrade, download data, analyse, strategize, subscribe with us
Details:
Sacubitril is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.
Lead Product(s): Sacubitril Sodium,Valsartan
Therapeutic Area: Undisclosed Brand Name: Undisclosed
Study Phase: Phase IProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable January 05, 2024
Lead Product(s) : Sacubitril Sodium,Valsartan
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
A Bioequivalence Study of Sacubitril/Valsartan Film-coated Tablets Under Fasting Conditions
Details : Sacubitril is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
January 05, 2024
Details:
Sacubitril is a neprilysin inhibitor and valsartan is an angiotensin II receptor blocker (ARB), the combination is indicated for the treatment of chronic heart failure and reduced ejection fraction.
Lead Product(s): Sacubitril Sodium,Valsartan
Therapeutic Area: Cardiology/Vascular Diseases Brand Name: Sacubitril-Valsartan-Generic
Study Phase: Approved FDFProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable August 19, 2025
Lead Product(s) : Sacubitril Sodium,Valsartan
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
MSN Launches Sacubitril/Valsartan Tablets In U.S. After Legal Win
Details : Sacubitril is a neprilysin inhibitor and valsartan is an angiotensin II receptor blocker (ARB), the combination is indicated for the treatment of chronic heart failure and reduced ejection fraction.
Product Name : Sacubitril-Valsartan-Generic
Product Type : Miscellaneous
Upfront Cash : Inapplicable
August 19, 2025
Details:
Sacubitril is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Heart Failure.
Lead Product(s): Sacubitril Sodium,Valsartan
Therapeutic Area: Cardiology/Vascular Diseases Brand Name: Undisclosed
Study Phase: Phase IProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable April 10, 2025
Lead Product(s) : Sacubitril Sodium,Valsartan
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase I
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Bioequivalence Study to Compare Sacubitril and Valsartan Tablets (97mg/103mg) Versus Entresto® ...
Details : Sacubitril is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Heart Failure.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
April 10, 2025
Details:
Entresto-Generic (sacubitril and valsartan) is an oral angiotensin receptor neprilysin inhibitor, which is approved for the treatment of chronic heart failure.
Lead Product(s): Sacubitril Sodium,Valsartan
Therapeutic Area: Cardiology/Vascular Diseases Brand Name: Entresto-Generic
Study Phase: Approved FDFProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable January 24, 2025
Lead Product(s) : Sacubitril Sodium,Valsartan
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lupin Receives U.S. FDA Approval for Sacubitril and Valsartan Tablets
Details : Entresto-Generic (sacubitril and valsartan) is an oral angiotensin receptor neprilysin inhibitor, which is approved for the treatment of chronic heart failure.
Product Name : Entresto-Generic
Product Type : Miscellaneous
Upfront Cash : Inapplicable
January 24, 2025
Details:
Sacubitril is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Essential Hypertension.
Lead Product(s): Sacubitril Sodium,Valsartan
Therapeutic Area: Cardiology/Vascular Diseases Brand Name: Undisclosed
Study Phase: Phase IIIProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable October 16, 2024
Lead Product(s) : Sacubitril Sodium,Valsartan
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Phase 3 Trial to Evaluate the Efficacy and Safety of CKD-202A
Details : Sacubitril is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Essential Hypertension.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
October 16, 2024
Details:
OnArni (sacubitril and valsartan) is an oral angiotensin receptor neprilysin inhibitor, which is approved for the treatment of chronic heart failure in 2 years and older patients.
Lead Product(s): Sacubitril Sodium,Valsartan
Therapeutic Area: Cardiology/Vascular Diseases Brand Name: OnArni
Study Phase: Approved FDFProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable October 15, 2024
Lead Product(s) : Sacubitril Sodium,Valsartan
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
USV Introduces OnArni, FDC of Sacubitril, Valsartan, For HF Management
Details : OnArni (sacubitril and valsartan) is an oral angiotensin receptor neprilysin inhibitor, which is approved for the treatment of chronic heart failure in 2 years and older patients.
Product Name : OnArni
Product Type : Miscellaneous
Upfront Cash : Inapplicable
October 15, 2024
Details:
Sacubright (sacubitril and valsartan) is an oral angiotensin receptor neprilysin inhibitor, which is approved for the treatment of chronic heart failure in 2 years and older patients.
Lead Product(s): Sacubitril Sodium,Valsartan
Therapeutic Area: Cardiology/Vascular Diseases Brand Name: Sacubright
Study Phase: Phase IIProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable October 04, 2024
Lead Product(s) : Sacubitril Sodium,Valsartan
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Exemed Receives CDSCO Nod For Study of Sacubitril Plus Valsartan Sustained-Release Tablet
Details : Sacubright (sacubitril and valsartan) is an oral angiotensin receptor neprilysin inhibitor, which is approved for the treatment of chronic heart failure in 2 years and older patients.
Product Name : Sacubright
Product Type : Miscellaneous
Upfront Cash : Inapplicable
October 04, 2024
Details:
Sacubitril and valsartan is an oral angiotensin receptor neprilysin inhibitor, which is approved for the treatment of chronic heart failure in 2 years and older patients.
Lead Product(s): Sacubitril Sodium,Valsartan
Therapeutic Area: Cardiology/Vascular Diseases Brand Name: Entresto-Generic
Study Phase: Approved FDFProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable September 02, 2024
Lead Product(s) : Sacubitril Sodium,Valsartan
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Biocon Unit Gets USFDA Nod For Generic Drug
Details : Sacubitril and valsartan is an oral angiotensin receptor neprilysin inhibitor, which is approved for the treatment of chronic heart failure in 2 years and older patients.
Product Name : Entresto-Generic
Product Type : Miscellaneous
Upfront Cash : Inapplicable
September 02, 2024
Details:
Enresto-Generic (sacubitril and valsartan) is an oral neprilysin inhibitor, is approved for the treatment of additional indication of adults chronic heart failure.
Lead Product(s): Sacubitril Sodium,Valsartan
Therapeutic Area: Cardiology/Vascular Diseases Brand Name: Entresto-Generic
Study Phase: Approved FDFProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable July 10, 2024
Lead Product(s) : Sacubitril Sodium,Valsartan
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Zydus Lifesciences gets USFDA nod to market chronic heart failure treatment drug
Details : Enresto-Generic (sacubitril and valsartan) is an oral neprilysin inhibitor, is approved for the treatment of additional indication of adults chronic heart failure.
Product Name : Entresto-Generic
Product Type : Miscellaneous
Upfront Cash : Inapplicable
July 10, 2024
Details:
A eneric formulation of sacubitril and valsartan, an oral neprilysin inhibitor, is approved for the treatment of additional indication of adults chronic heart failure.
Lead Product(s): Sacubitril Sodium,Valsartan
Therapeutic Area: Cardiology/Vascular Diseases Brand Name: Entresto-Generic
Study Phase: Approved FDFProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable May 29, 2024
Lead Product(s) : Sacubitril Sodium,Valsartan
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Alembic Pharmaceuticals receives USFDA final approval for Sacubitril and Valsartan Tablets
Details : A eneric formulation of sacubitril and valsartan, an oral neprilysin inhibitor, is approved for the treatment of additional indication of adults chronic heart failure.
Product Name : Entresto-Generic
Product Type : Miscellaneous
Upfront Cash : Inapplicable
May 29, 2024
Related Excipient Companies
Excipients by Applications
Market Place
Patents & EXCLUSIVITIES
REF. STANDARDS & IMPURITIES
ABOUT THIS PAGE
36
PharmaCompass offers a list of Sacubitril Sodium API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Sacubitril Sodium manufacturer or Sacubitril Sodium supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Sacubitril Sodium manufacturer or Sacubitril Sodium supplier.
PharmaCompass also assists you with knowing the Sacubitril Sodium API Price utilized in the formulation of products. Sacubitril Sodium API Price is not always fixed or binding as the Sacubitril Sodium Price is obtained through a variety of data sources. The Sacubitril Sodium Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.
A Sacubitril Sodium manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Sacubitril Sodium, including repackagers and relabelers. The FDA regulates Sacubitril Sodium manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Sacubitril Sodium API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Sacubitril Sodium manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A Sacubitril Sodium supplier is an individual or a company that provides Sacubitril Sodium active pharmaceutical ingredient (API) or Sacubitril Sodium finished formulations upon request. The Sacubitril Sodium suppliers may include Sacubitril Sodium API manufacturers, exporters, distributors and traders.
click here to find a list of Sacubitril Sodium suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A Sacubitril Sodium DMF (Drug Master File) is a document detailing the whole manufacturing process of Sacubitril Sodium active pharmaceutical ingredient (API) in detail. Different forms of Sacubitril Sodium DMFs exist exist since differing nations have different regulations, such as Sacubitril Sodium USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A Sacubitril Sodium DMF submitted to regulatory agencies in the US is known as a USDMF. Sacubitril Sodium USDMF includes data on Sacubitril Sodium's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Sacubitril Sodium USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of Sacubitril Sodium suppliers with USDMF on PharmaCompass.
A Sacubitril Sodium written confirmation (Sacubitril Sodium WC) is an official document issued by a regulatory agency to a Sacubitril Sodium manufacturer, verifying that the manufacturing facility of a Sacubitril Sodium active pharmaceutical ingredient (API) adheres to the Good Manufacturing Practices (GMP) regulations of the importing country. When exporting Sacubitril Sodium APIs or Sacubitril Sodium finished pharmaceutical products to another nation, regulatory agencies frequently require a Sacubitril Sodium WC (written confirmation) as part of the regulatory process.
click here to find a list of Sacubitril Sodium suppliers with Written Confirmation (WC) on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Sacubitril Sodium as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for Sacubitril Sodium API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture Sacubitril Sodium as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain Sacubitril Sodium and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Sacubitril Sodium NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of Sacubitril Sodium suppliers with NDC on PharmaCompass.
Sacubitril Sodium Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Sacubitril Sodium GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Sacubitril Sodium GMP manufacturer or Sacubitril Sodium GMP API supplier for your needs.
A Sacubitril Sodium CoA (Certificate of Analysis) is a formal document that attests to Sacubitril Sodium's compliance with Sacubitril Sodium specifications and serves as a tool for batch-level quality control.
Sacubitril Sodium CoA mostly includes findings from lab analyses of a specific batch. For each Sacubitril Sodium CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Sacubitril Sodium may be tested according to a variety of international standards, such as European Pharmacopoeia (Sacubitril Sodium EP), Sacubitril Sodium JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Sacubitril Sodium USP).